Incyte Genomics Inc
INCY Real Time Price USDRecent trades of INCY by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in INCY holdings by institutional investors
Quarterly net insider trading by INCY's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$330,000 Oct 20, 2025 Issue: Medicare/Medicaid
-
$520,000 Jul 21, 2025 Issue: Medicare/Medicaid
-
$240,000 Apr 21, 2025 Issue: Medicare/Medicaid
-
$350,000 Feb 21, 2025 Issue: Medicare/Medicaid
-
$220,000 Oct 21, 2024 Issue: Medicare/Medicaid
-
$300,000 Jul 22, 2024 Issue: Medicare/Medicaid
-
$200,000 Apr 22, 2024 Issue: Medicare/Medicaid
-
$460,000 Apr 22, 2024 Issue: Medicare/Medicaid
-
$360,000 Oct 20, 2023 Issue: Medicare/Medicaid
-
$220,000 Jul 20, 2023 Issue: Medicare/Medicaid
-
$180,000 Jan 20, 2023 Issue: Copyright/Patent/Trademark Medicare/Medicaid
-
$220,000 Oct 20, 2022 Issue: Copyright/Patent/Trademark Medicare/Medicaid
-
$200,000 Jul 21, 2022 Issue: Taxation/Internal Revenue Code Medicare/Medicaid
-
$280,000 Apr 20, 2022 Issue: Medicare/Medicaid
-
$110,000 Jan 21, 2022 Issue: MEDICARE/MEDICAID
-
$190,000 Oct 20, 2021 Issue: MEDICARE/MEDICAID
-
$500,000 Jul 20, 2021 Issue: MEDICARE/MEDICAID
-
$200,000 Apr 20, 2021 Issue: MEDICARE/MEDICAID
-
$50,000 Jan 21, 2021 Issue: Health Issues
-
$50,000 Jan 20, 2021 Issue: None
-
$20,000 Jan 19, 2021 Issue: None
-
$50,000 Oct 20, 2020 Issue: Health Issues
-
$50,000 Oct 20, 2020 Issue: MEDICARE/MEDICAID
-
$50,000 Jul 20, 2020 Issue: MEDICARE/MEDICAID
-
$50,000 Jul 20, 2020 Issue: Medicare/Medicaid
-
$50,000 Apr 27, 2020 Issue: MEDICARE/MEDICAID
-
$50,000 Apr 17, 2020 Issue: Medicare/Medicaid
-
$30,000 Jan 21, 2020 Issue: MEDICARE/MEDICAID
-
$30,000 Jan 18, 2020 Issue: Medicare/Medicaid
-
$20,000 Mar 26, 2003 Issue: Copyright/Patent/Trademark
-
$20,000 Aug 22, 2002 Issue: Copyright/Patent/Trademark
-
$20,000 Mar 14, 2002 Issue: Copyright/Patent/Trademark
-
$60,000 Feb 20, 2002 Issue: None
-
$20,000 Sep 28, 2001 Issue: Copyright/Patent/Trademark
-
$60,000 Feb 15, 2000 Issue: Medical/Disease Research/Clinical Labs
-
$40,000 Aug 16, 1999 Issue: Medical/Disease Research/Clinical Labs
INCY Estimated quarterly lobbying spending
INCY Revenue by Segment or Geography
New INCY patent grants
-
Patent Title: Piperidin-4-yl azetidine derivatives as jak1 inhibitors Jun. 19, 2018
-
Patent Title: Cyclopropylamines as lsd1 inhibitors Jun. 12, 2018
-
Patent Title: Crystalline forms of a pi3k inhibitor Jun. 05, 2018
-
Patent Title: Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors Jun. 05, 2018
-
Patent Title: Pyrrolotriazine compounds as tam inhibitors May. 29, 2018
-
Patent Title: Pyrimidinones as pi3k inhibitors May. 22, 2018
-
Patent Title: Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors May. 22, 2018
-
Patent Title: 1h-pyrrolo[2,3,c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins May. 01, 2018
-
Patent Title: Amido compounds and their use as pharmaceuticals May. 01, 2018
-
Patent Title: Heterocyclic compounds as lsd1 inhibitors Apr. 17, 2018
-
Patent Title: Bicyclic azaheterocyclobenzylamines as pi3k inhibitors Apr. 17, 2018
-
Patent Title: Imidazotriazines and imidazopyrimidines as kinase inhibitors Apr. 17, 2018
-
Patent Title: Tricyclic heterocycles as bet protein inhibitors Apr. 10, 2018
-
Patent Title: Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders Apr. 03, 2018
-
Patent Title: Bipyrazole derivatives as jak inhibitors Mar. 27, 2018
-
Patent Title: Heterocyclic compounds useful as pim kinase inhibitors Mar. 20, 2018
-
Patent Title: Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as bet protein inhibitors Mar. 20, 2018
-
Patent Title: Secreted proteins Mar. 13, 2018
-
Patent Title: Tricyclic fused thiophene derivatives as jak inhibitors Mar. 06, 2018
-
Patent Title: Processes for preparing pyrazolyl-substituted pyrrolo[2,3-d]pyrimidines Mar. 06, 2018
-
Patent Title: Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors Feb. 13, 2018
-
Patent Title: Bicyclic heterocycles as fgfr4 inhibitors Feb. 13, 2018
-
Patent Title: Methods for detecting expression levels of human signal peptide-containing proteins (hspp) Feb. 06, 2018
-
Patent Title: Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b] pyrimidin-5-yl-amines as janus kinase inhibitors Jan. 30, 2018
-
Patent Title: Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 Jan. 23, 2018
-
Patent Title: Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor Jan. 23, 2018
-
Patent Title: Salts of a pim kinase inhibitor Jan. 09, 2018
-
Patent Title: Tricyclic heterocycles as bet protein inhibitors Dec. 26, 2017
-
Patent Title: Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors Dec. 26, 2017
-
Patent Title: Heterocyclic compounds and uses thereof Dec. 12, 2017
-
Patent Title: Tricyclic heterocycles as bet protein inhibitors Dec. 05, 2017
-
Patent Title: Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors Nov. 21, 2017
-
Patent Title: N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors Nov. 14, 2017
-
Patent Title: Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors Nov. 14, 2017
-
Patent Title: Processes of preparing a jak1 inhibitor and new forms thereto Oct. 31, 2017
-
Patent Title: Pyridineamine compounds useful as pim kinase inhibitors Oct. 31, 2017
-
Patent Title: Bicyclic heterocycles as fgfr4 inhibitors Oct. 31, 2017
-
Patent Title: Aza spiro alkane derivatives as inhibitors of metalloproteases Oct. 31, 2017
-
Patent Title: 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase Oct. 17, 2017
-
Patent Title: Tricyclic fused thiophene derivatives as jak inhibitors Oct. 03, 2017
-
Patent Title: Tricyclic heterocycles as bet protein inhibitors Oct. 03, 2017
-
Patent Title: Triazolopyridines and triazolopyrazines as lsd1 inhibitors Sep. 12, 2017
-
Patent Title: Substituted pyrrolo[2,3-b]pyrazines as fgfr inhibitors Aug. 29, 2017
-
Patent Title: Bicyclic heterocycles as bet protein inhibitors Aug. 22, 2017
-
Patent Title: Process for the synthesis of a phosphoinositide 3-kinase inhibitor Aug. 15, 2017
-
Patent Title: Heterocyclylamines as pi3k inhibitors Aug. 15, 2017
-
Patent Title: Processes and intermediates for making a jak inhibitor Aug. 01, 2017
-
Patent Title: Processes and intermediates for making a jak inhibitor Jul. 25, 2017
-
Patent Title: Fused bicyclic 1,2,4-triazine compounds as tam inhibitors Jul. 18, 2017
-
Patent Title: Bicyclic heterocycles as fgfr4 inhibitors Jul. 18, 2017
Federal grants, loans, and purchases
- $541,104 2025-04-28 00:00:00 Agency: Department of Veterans Affairs
- $119,619 2024-07-02 00:00:00 Agency: Department of Veterans Affairs
- $541,104 2024-04-15 00:00:00 Agency: Department of Veterans Affairs
- $13,291 2024-03-15 00:00:00 Agency: Department of Veterans Affairs
- $13,291 2024-01-26 00:00:00 Agency: Department of Veterans Affairs
- $12,725 2024-01-12 00:00:00 Agency: Department of Veterans Affairs
- $12,725 2023-12-12 00:00:00 Agency: Department of Veterans Affairs
- $12,725 2023-11-29 00:00:00 Agency: Department of Veterans Affairs
- $12,725 2023-11-03 00:00:00 Agency: Department of Veterans Affairs
- $12,725 2023-09-25 00:00:00 Agency: Department of Veterans Affairs
- $12,874 2023-07-28 00:00:00 Agency: Department of Veterans Affairs
- $12,725 2023-06-13 00:00:00 Agency: Department of Veterans Affairs
- $12,874 2023-05-02 00:00:00 Agency: Department of Veterans Affairs
- $12,812 2023-04-20 00:00:00 Agency: Department of Veterans Affairs
- $675,000 2023-04-11 00:00:00 Agency: Department of Veterans Affairs
- $38,199 2023-03-15 00:00:00 Agency: Department of Veterans Affairs
- $82,626 2022-06-30 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $76,351 2022-04-27 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $499,918 2022-02-18 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $0 2022-02-04 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $320,250 2021-10-29 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $12,725 2021-08-06 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $12,725 2021-06-29 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $101,802 2021-01-19 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
Estimated quarterly amount awarded to INCY from public contracts
Recent insights relating to INCY
Recent picks made for INCY stock on CNBC
ETFs with the largest estimated holdings in INCY
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $INCY stock a Buy, Sell, or Hold?
- What is the price target for $INCY stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $INCY stock?
- Who owns the most shares of $INCY stock?
- What funds own $INCY stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view INCY Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
- Address Wilmington, DE
- Market Cap 20.0 billion
- Employees 2,617
- Industrial Classification Services-Commercial Physical & Biological Research